11 completed, 10 recruiting, 6 unknown, 3 active not recruiting. 18 Phase 2, 5 Phase 1, 4 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Hormone Receptor Positive Tumor: new trials by email Literature Review of Hormone Receptor Positive Tumor trials Research Report on Hormone Receptor Positive Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the TheraBionic P1 Device in Breast Cancer TheraBionic P1 Device - Breast Cancer Stage I, Breast Cancer Stage II | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 24 | 2026-10-01 | 2026-04-21 |
| Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors RGT-490 - Breast Cancer, Ovarian Cancer | Phase 1 | Recruiting | Regor Pharmaceuticals Inc. | 63 | 2026-06-01 | 2026-07-22 |
| A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer TheraBionic P1 - HER2-negative Breast Cancer, Hormone Receptor Positive Tumor | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 82 | 2026-01-16 | 2026-08-26 |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer Zovegalisib, Capivasertib, Fulvestrant - PIK3CA Mutation, HER2- Negative Breast Cancer | Phase 3 | Recruiting | Relay Therapeutics, Inc. | 540 | 2025-08-26 | 2026-10-05 |
| Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer Early Breast Cancer, Hormone Receptor Positive Tumor | Recruiting | Institute of Oncology Ljubljana | 319 | 2025-01-05 | 2026-03-06 | |
| First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors RLY-5836, Fulvestrant, Palbociclib - PIK3CA Mutation, Solid Tumor, Adult | Phase 1 | Completed | Relay Therapeutics, Inc. | 41 | 2023-03-29 | 2025-05-16 |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer INX-315, Fulvestrant, Abemaciclib - Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Incyclix Bio | 150 | 2023-03-28 | 2026-04-01 |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Elacestrant, Triptorelin, Tamoxifen 20 mg - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 96 | 2023-02-03 | 2026-04-24 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
| Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer Abemaciclib, Fulvestrant, Aromatase Inhibitors - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Completed | Duke University | 18 | 2020-09-14 | 2025-07-20 |
| Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Talazoparib, ASTX727 - Metastatic Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Completed | Kathy Miller | 34 | 2020-04-01 | 2024-03-22 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Pyrotinib, Trastuzumab, Aromatase Inhibitors - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Fuzhou General Hospital | 77 | 2019-11-01 | 2019-09-12 |
| Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Tamoxifen Citrate - Breast Cancer Female, Hormone Receptor Positive Tumor | Phase 2 | Active not recruiting | British Columbia Cancer Agency | 290 | 2019-09-23 | 2023-06-15 |
| Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC Pyrotinib, Trastuzumab, Aromatase inhibitor - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 250 | 2019-06-01 | 2019-04-10 |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer Durvalumab, Anastrozole 1mg, Letrozole 2.5mg - Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2019-04-26 | 2022-05-31 |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) Palbociclib, Endocrine therapy - Breast Cancer, Advanced Breast Cancer | Phase 2 | Completed | MedSIR | 198 | 2019-04-05 | 2023-09-07 |
| Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) OPERA - Breast Cancer, Hormone Receptor Positive Tumor | Not applicable | Completed | Azienda Ospedaliero-Universitaria Careggi | 53 | 2018-11-01 | 2019-11-13 |
| Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer Multi-parameter tests - Breast Cancer, Breast Neoplasms | Active not recruiting | Oslo University Hospital | 2300 | 2018-10-29 | 2025-08-08 | |
| Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] - Breast Neoplasm Female, Stage I Breast Cancer | Early Phase 1 | Unknown | Institut Català d'Oncologia | 60 | 2018-07-05 | 2021-11-03 |
Showing 20 of 31. Sign in to see all of them.
Breast Neoplasms (29) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (3) · Breast Diseases (2) · Endometrial Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Arthralgia (1) · Carcinoma (1) · Hemangiosarcoma (1) · Medication Adherence (1) · Motor Activity (1) · Osteopetrosis, Autosomal Recessive 7 (1) · Osteopetrosis, mild autosomal recessive form (1) · Pathologic Complete Response (1)
Neoplasms by Site (30) · Skin Diseases (29) · Skin and Connective Tissue Diseases (29) · Neoplasms (28) · Breast Diseases (27) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · Neoplastic Processes (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3)
Fulvestrant (9) · Letrozole (9) · Anastrozole (7) · Aromatase Inhibitors (7) · exemestane (6) · abemaciclib (5) · Tamoxifen (4) · Trastuzumab (4) · palbociclib (4) · Goserelin (3) · pyrotinib (3) · Bevacizumab (2) · Carboplatin (2) · Cyclophosphamide (2) · Drug Evaluation (2)
Barbara Ann Karmanos Cancer Institute (2) · Fudan University (2) · Oslo University Hospital (2) · Relay Therapeutics, Inc. (2) · iOMEDICO AG (2) · Azienda Ospedaliero-Universitaria Careggi (1) · British Columbia Cancer Agency (1) · Centre Leon Berard (1) · Consorzio Oncotech (1) · Duke University (1) · Eli Lilly and Company (1) · Fuzhou General Hospital (1) · GBG Forschungs GmbH (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Incyclix Bio (1)
United States (11) · Germany (6) · Italy (5) · Spain (5) · Canada (4) · Australia (3) · Belgium (3) · China (3) · France (3) · Austria (2) · Netherlands (2) · Norway (2) · Slovenia (2) · South Korea (2) · Taiwan (2)
Caroline Lohrisch, MC (1) · Chen Xi, PhD (1) · Elgene Lim, MBBS FRACP PhD (1) · Erika Matos, PhD (1) · Hung Khong, MD (1) · Isacco Desideri, MD (1) · Jon Amund Kyte (1) · Jonas Bergh, Professor (1) · Kathy Miller, MD (1) · Laura Esserman, MD, MBA (1) · Lorenzo Livi, MD (1) · Lubina Arjyal, M.D. (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 31615937, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32620163, PMID 32660609, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35076812, PMID 35551299, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36356410, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38242720, PMID 38362377, PMID 38745646, PMID 38979716, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40294349, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41697438, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224
2014 (2), 2016 (1), 2017 (1)